Why TMAO resonates with AAA biology?
Dietary choline and carnitine are converted by gut microbial TMA‑lyase pathways (e.g.
cut C/D,
cnt A/B) to trimethylamine (TMA), which hepatic flavin-containing monooxygenase 3 (FMO3) then oxidizes to trimethylamine‑N‑oxide (TMAO)[
3,
4]. Beyond being a circulating analyte, TMAO can heighten platelet reactivity, amplify inflammatory signaling, and tilt the milieu toward thrombosis—pathophysiological processes that plausibly accelerate aneurysm growth[
5,
6]. Mechanistic reviews and preclinical studies converge on the same point: dampening microbial TMA formation or modulating FMO3 lowers TMAO and curbs aneurysm growth/rupture in mice, lending a human-animal link consistent with the JAMA Cardiology observations[
1,
4–
7]. Work on dysbiosis further implicates shifts in bacterial communities, neutrophil extracellular traps (NETs) formation, and even mycobiome imbalance in extracellular‑matrix breakdown and immune‑microenvironment remodeling[
8]. These elements jointly support a microbe-metabolite-immune-matrix coupling relevant to AAA biology.
Incremental value beyond imaging
No single metabolite can capture the multipathway nature of AAA. Recent multi‑omic studies—combining targeted proteomics with metabolomics and ratio‑based features—link disturbances in the glutathione-serine-glycine axis, lipid mediators, and amino‑acid pathways with aneurysm size and growth; Mendelian-randomization screens, which currently provide the strongest human causal evidence, point to additional metabolite classes with putative causal roles, although this remains genetic rather than interventional evidence[
9–
12]. A practical next step is to pair TMAO with complementary microbiome‑derived metabolites such as phenylacetylglutamine (PAGln), which increases platelet reactivity via adrenergic signaling, and potentially protective short‑chain fatty acids (SCFAs), alongside inflammatory/thrombotic readouts (e.g. NET composites like MPO–DNA or H3Cit, soluble GPVI, D‑dimer)[
5,
8,
10,
13]. When combined with imaging measures—maximal diameter, growth rate, and intraluminal thrombus (ILT) volume—these features could form a modular “microbiome-metabolite-immune” risk framework. The added value should be quantified with net reclassification improvement/integrated discrimination improvement (NRI/IDI) and decision‑curve analysis, benchmarked to ESVS 2024 surveillance and intervention guidance[
2,
14].
Assay accessibility & standardization
The JAMA Cardiology study used stable‑isotope–dilution LC–MS/MS, a current reference method for TMAO quantification[
1]. Wider adoption will require progress on three fronts: (1) reference intervals and pre‑analytical variables (fasting status, recent diet/medications, kidney function; plasma
vs serum) to enable interpretable, cross‑center comparisons; (2) methodological streamlining, with lower‑cost LC–MS/MS panels that also quantify precursors (choline/carnitine) and companion metabolites under robust external quality assurance[
15]; and (3) cautious use of enzyme-linked immunosorbent assays (ELISAs)—suitable for exploratory work but not for decision‑making without formal method‑comparison against isotope‑dilution LC–MS/MS.
From biomarker to target: an intervention pathway
While Mendelian-randomization provides compelling genetic evidence for a causal role of TMAO in AAA, the ultimate translational proof requires demonstrating that pharmacological or dietary lowering of TMAO retards aneurysm progression in humans. This constitutes a crucial “causality gap” that early-phase functional-endpoint trials are designed to address. Success in such trials would transform TMAO from a risk marker into a bona fide therapeutic target[
3].
TMAO is not only a risk marker but also an actionable target[
3]. Early-phase human studies could evaluate dietary and microbiome-directed interventions (such as non-lethal TMA-lyase inhibition) with appropriate safety monitoring[
16,
17]; explore host-pathway modulation (e.g. FMO3) where robust preclinical data exist[
4,
18–
20]; and evaluate rational combinations with antiplatelet or anti-inflammatory therapies, informed by the underlying platelet/NET biology. Useful pharmacodynamic readouts include ΔTMAO, changes in NETs/platelet reactivity, and AAA growth rate, alongside time‑to‑repair and safety.
A pragmatic translational roadmap
A practical translational plan can move through five steps: (1) Validation and calibration. Externally verify the ~6.2 µM cut‑point (and any data‑driven alternatives), include subgroup analyses, and report discrimination (C‑statistic), reclassification (NRI/IDI), and net benefit. (2) Multi‑metabolite scoring. Build parsimonious models that combine TMAO with PAGln and SCFAs, plus NETs/proteomic markers, and show clear gain beyond imaging alone. (3) Functional‑endpoint trials. In surveillance cohorts with small‑to‑medium AAAs, treat ΔTMAO, NETs composites, and platelet reactivity as functional endpoints—co‑primary or key secondary—alongside diameter growth and time‑to‑intervention, in line with the “Beyond Diameter” agenda. (4) Intervention pilots. Test TMA‑lyase inhibitors, diet/microbiome programs, and FMO3 modulation; aim for a bridgeable evidence chain (metabolite change → biomarker change → slower growth). (5) Deployment. Standardize isotope‑dilution LC–MS/MS, harmonize pre‑analytical handling across sites, and institute external proficiency testing to enable an in vitro diagnostic (IVD)–compliant deployment rollout. (6) Health-system integration and adoption. Looking beyond biomarker validation and trial efficacy, successful deployment will require overcoming real-world implementation barriers. This includes demonstrating cost-effectiveness against current standards of care, developing clear reimbursement pathways for novel biomarker testing, and seamlessly integrating the “microbiome–metabolite–immune” risk score into existing clinical workflows. Engaging patients and clinicians early about the value of “Beyond Diameter” monitoring will be critical for acceptance and sustained use.
Concluding perspective
This JAMA Cardiology work expands TMAO from an atherosclerosis-associated analyte to a clinically operational biomarker for AAA growth and surgical risk, supporting emerging evidence that dysbiosis, NETs, and microbiome‑derived metabolic networks shape aneurysm biology. The next horizon is not merely better risk stratification but a biomarker‑to‑target continuum: if we can measure these molecules accurately and reproducibly, and demonstrate in functional‑endpoint trials that lowering TMAO tracks with slower AAA growth and delayed repair, then AAA surveillance and treatment can truly move beyond diameter toward mechanistically guided care.
PDF
(229KB)
